Satellos Bioscience Inc. — Investor Relations & Filings

Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing regenerative small molecule therapeutics for degenerative muscle diseases, primarily Duchenne muscular dystrophy (DMD). The company's core mission is to restore the body's natural ability to regenerate muscle, addressing the failure of muscle repair inherent in these conditions. Satellos utilizes a novel approach rooted in muscle biology, focusing on restoring the asymmetric division of muscle stem cells (satellite cells), a process disrupted by the absence of dystrophin in DMD. Their strategy involves targeting the AAK1 protein to reactivate the natural repair mechanism. The lead therapeutic candidate, SAT-3247, is currently advancing into a Pediatric Phase 2 clinical study for DMD.